Factors Influencing the Use of Mobile Apps and Wearables: Pre- and Post-Surgery Quality of Life Assessment Study

Background: Quality of life (QoL) is an important surgical outcome, commonly assessed through self-reports, and has the potential to be enhanced by objective information from personal technologies such as smartphone apps and wearables. Understanding patients’ perspectives on this application of personal technologies is scarce. Objective: This study aimed to identify operational aspects of smartphone- and wearable-based assessments, as well as human and operational factors that may influence the acceptability of already owned (mostly smartphone) or new (mostly wearable) technologies by patients for pre- and post-surgery QoL assessments. Methods: Through purposive sampling, 41 patients from 3 health care centers in Switzerland, the United States, and the United Kingdom, who were undergoing or scheduled for surgery for degenerative cervical myelopathy (DCM), liver transplantation, or total hip replacement, were interviewed about their perceptions of QoL, current use of smartphones, health apps, and wearables for self-management and their views on using these technologies to assess QoL before and after surgery. Results: Across the 3 studies (n=41), most (n=36) patients reported improved QoL after surgery, mainly due to reduced pain and fatigue and regained autonomy, while a few patients with DCM reported no change (n=2) or worsening (n=1). Patients were generally comfortable using smartphones and tablets, but few (n=4) used them for health management. Wearables were perceived differently across groups: they were well accepted in transplant@US, moderately in hip@UK, and least in myelopathy@CH. Many patients with DCM found wearables “useless,” believing they added little to their self-awareness or recovery and could not replace human clinical judgment. Others expressed concerns about privacy, complexity, notifications, and battery life, while some acknowledged their motivational value when the data were clearly interpreted. Despite varying acceptance levels, most participants said they would consider using such devices if they contributed to research or improved care. Conclusions: Given a mostly negative attitude of patients toward wearables, we discuss the use of smartphone-based automated logging of physical functioning (sleep and physical activity) instead. Such logging may be less accurate than a dedicated wearable, but it may be accurate enough to measure their pre- and post-surgery physical functioning changes. Additionally, a smartphone has the advantage of being already well integrated into the daily life of patients from the perspective of its functionality and the patients’ routines, contrary to wearable devices, which would have been provided to the patients in the context of pre- and post-surgery clinical care and require additional attention for their continuous wear, charging, and data synchronization, among others.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/bcd470214df20bf7565f949b56fb5ae1" />

Regulatory tips from a breakthrough noninvasive device startup

Compremium’s noninvasive Quantis CVP (central venous pressure) measurement device joined the FDA’s Total Product Life Cycle Advisory Program (TAP) after earning Breakthrough Device designation in January 2026. The FDA designed TAP to “help spur more rapid development of high-quality, safe, effective, and innovative medical devices that are critical to public health” and expedite patient access…

The post Regulatory tips from a breakthrough noninvasive device startup appeared first on Medical Design and Outsourcing.

Henry Schein discloses exec pay for longtime CEO Stan Bergman’s final year

Henry Schein reported pay increases for three of its five executives in 2025, while median employee pay increased from the year before. The Melville, New York-based medical product supplier is the 11th-largest medical device company in the world, according to Medical Design & Outsourcing’s 2025 Medtech Big 100 ranking by revenue. Since then, Henry Schein increased…

The post Henry Schein discloses exec pay for longtime CEO Stan Bergman’s final year appeared first on Medical Design and Outsourcing.

Freudenberg Medical launches ISO Class 5 cleanroom for biopharma

NEWS RELEASE: Freudenberg Medical launches CleanAssure, an ISO class 5 controlled cleanroom for sterile single-use assemblies New controlled cleaning and sterilization service supports biopharma customers with ready-to-use single-use assemblies Kaiserslautern, Germany — Freudenberg Medical, a global contract design and manufacturing partner to the medical device and biopharma industry, announced the launch of CleanAssure, a new ISO…

The post Freudenberg Medical launches ISO Class 5 cleanroom for biopharma appeared first on Medical Design and Outsourcing.

How ZB’s Paragon 28 created a novel curved foot nail system

At Paragon 28, now part of Zimmer Biomet, engineers asked if there was a better implant shape to support foot and ankle anatomy. It took three novel instruments and a novel implant to make it a reality. When Paragon 28 Director of Engineering Ken Roggow and his team approached the drawing board to design a…

The post How ZB’s Paragon 28 created a novel curved foot nail system appeared first on Medical Design and Outsourcing.

Use of Wearable Devices to Augment Traditional Measurements of Postoperative Outcomes Following Total Joint Arthroplasty: Systematic Review

Background: Wearable devices enabling remote monitoring by surgeons of their patients have gained prominence around total joint arthroplasty (TJA), offering continuous patient data to identify those not meeting postoperative goals, thereby facilitating timely interventions. While multiple studies highlight the utility of these devices in tracking postoperative progress, a standardized approach to their application is lacking. This review aims to synthesize existing literature on the use of wearable device-tracked activity for monitoring TJA outcomes. Objective: We examined the current literature to evaluate how wearable devices are used in monitoring and improving patient rehabilitation and outcomes following TJA. Methods: A systematic review was conducted following Cochrane methodology. A literature search of all available literature was performed in April 2024 and identified 102 studies to undergo full-text review. Systematic reviews, duplicate papers, and theoretical papers were excluded. Ultimately, 35 studies met the selection criteria. Results: The review revealed that 32 of 35 (91.4%) studies used wearable devices to monitor step counts. A total of 21 (60%) studies incorporated joint-specific patient-reported outcome measures, though the specific measures varied. Further, 9 studies used standardized performance-based outcome measures, which also differed across studies. Finally, 7 (20%) studies collected sleep data; however, the methods and outcomes for sleep measurement were inconsistent among these studies. Conclusions: Remote monitoring via wearable devices offers a novel approach to tracking outcomes in TJA patients. Although the use of these devices in perioperative care is expanding, significant variability exists in the data reported across studies. Wearable monitoring is often integrated with patient-reported outcome measures and standardized functional assessments, yet the optimal data parameters that best correlate with established outcome metrics remain undefined. Additionally, data collected by wearables has not yet been shown to predict patient recovery or satisfaction. Further research is essential to refine these data parameters and the development of postoperative protocols that leverage wearable devices to enhance patient compliance and improve clinical outcomes. Trial Registration: PROSPERO CRD420261346230; https://www.crd.york.ac.uk/PROSPERO/view/CRD420261346230
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/84cacc21227b2261fe37fe6071778bab" />

The first year-long CGM implant developer isn’t done yet

Senseonics became the first company to bring a year-long continuous glucose monitor (CGM) to market with the launch of its Eversense 365 implantable system in 2024. The sensor system is different than existing transcutaneous sensors from Abbott and Dexcom, which use a small needle to measure glucose in the interstitial fluid under a patient’s skin…

The post The first year-long CGM implant developer isn’t done yet appeared first on Medical Design and Outsourcing.